evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
Published 1 year ago • 126 plays • Length 4:21Download video MP4
Download video MP3
Similar videos
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
1:09:08
hematuria evaluation with dr. stephen lieberman - may 04, 2021
-
45:01
understanding immunological testing: what do my lab tests mean?
-
7:32
does luspatercept reduce blood transfusions in mds patients?
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
0:56
luspatercept for mds-associated anemia
-
2:26
ace-536-mf-001 update: luspatercept for the treatment of anemia in myelofibrosis
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
1:31
overall survival of patients following treatment with luspatercept in the medalist trial
-
1:49
evaluating erythroid precursors in patients with lr-mds to predict response to esas
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
2:30
medalist: luspatercept and erythropoiesis biomarkers in mds